Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations
Titel:
Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations
Auteur:
Xiong, Kai Yang, Yi Yang, Yanan Wang, Zhengbo Liu, Yun Duo, Hong Yuan, Xinya Xiao, Yao Xiao, He Yang, Xueqin